|
1
|
Sloma I, Jiang X, Eaves AC and Eaves CJ:
Insights into the stem cells of chronic myeloid leukemia. Leukemia.
24:1823–1833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fojo A, Hamilton TC, Young RC and Ozols
RF: Multidrug resistance in ovarian cancer. Cancer. 60:(Suppl 8).
S2075–S2080. 1987. View Article : Google Scholar
|
|
3
|
Zinzi L, Capparelli E, Cantore M, Contino
M, Leopoldo M and Colabufo NA: Small and innovative molecules as
new strategy to revert MDR. Front Oncol. 4:22014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hendrikx JJ, Lagas JS, Rosing H, Schellens
JH, Beijnen JH and Schinkel AH: P-glycoprotein and cytochrome P450
3A act together in restricting the oral bioavailability of
paclitaxel. Int J Cancer. 132:2439–2447. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu H, Liu Z, Tang L, Liu J, Zhou M, Xie
F, Wang Z, Wang Y, Shen S, Hu L, et al: Reversal of P-gp and
MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from
Gynostemma pentaphyllum, in vincristine-resistant human oral
cancer (KB/VCR) cells. Eur J Pharmacol. 696:43–53. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsuji K, Wang YH, Takanashi M, Odajima T,
Lee GA, Sugimori H and Motoji T: Overexpression of lung
resistance-related protein and P-glycoprotein and response to
induction chemotherapy in acute myelogenous leukemia. Hematol Rep.
4:e182012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang LS, Li L, Li L, Chu S, Shiang KD, Li
M, Sun HY, Xu J, Xiao FJ, Sun G, et al: MicroRNA-486 regulates
normal erythropoiesis and enhances growth and modulates drug
response in CML progenitors. Blood. 125:1302–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Yuan Y, Tao K, Wang X, Xiao Q, Huang
Z, Zhong L, Cao W, Wen J and Feng W: Inhibition of BCR/ABL protein
expression by miR-203 sensitizes for imatinib mesylate. PLoS One.
8:e618582013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsai KW, Liao YL, Wu CW, Hu LY, Li SC,
Chan WC, Ho MR, Lai CH, Kao HW, Fang WL, et al: Aberrant
hypermethylation of miR-9 genes in gastric cancer.
Epigenetics. 6:1189–1197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H, Qi M, Li S, Qi T, Mei H, Huang K,
Zheng L and Tong Q: microRNA-9 targets matrix metalloproteinase 14
to inhibit invasion, metastasis, and angiogenesis of neuroblastoma
cells. Mol Cancer Ther. 11:1454–1466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heller G, Weinzierl M, Noll C, Babinsky V,
Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Döme B,
End-Pfützenreuter A, et al: Genome-wide miRNA expression profiling
identifies miR-9-3 and miR-193a as targets for DNA
methylation in non-small cell lung cancers. Clin Cancer Res.
18:1619–1629. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang LQ, Kwong YL, Kho CS, Wong KF, Wong
KY, Ferracin M, Calin GA and Chim CS: Epigenetic inactivation of
miR-9 family microRNAs in chronic lymphocytic leukemia -
implications on constitutive activation of NFκB pathway. Mol
Cancer. 12:1732013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rao X, Di Leva G, Li M, Fang F, Devlin C,
Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP:
MicroRNA-221/222 confers breast cancer fulvestrant resistance by
regulating multiple signaling pathways. Oncogene. 30:1082–1097.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang H, Kong W, He L, Zhao JJ, O'Donnell
JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al:
MicroRNA expression profiling in human ovarian cancer:
miR-214 induces cell survival and cisplatin resistance by
targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou M, Zeng J, Wang X, Guo Q, Huang T,
Shen H, Fu Y, Wang L, Jia J and Chen C: MiR-370 sensitizes chronic
myeloid leukemia K562 cells to homoharringtonine by targeting
Forkhead box M1. J Transl Med. 11:2652013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weng H, Huang H, Dong B, Zhao P, Zhou H
and Qu L: Inhibition of miR-17 and miR-20a by oridonin triggers
apoptosis and reverses chemoresistance by derepressing BIM-S.
Cancer Res. 74:4409–4419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishioka C, Ikezoe T, Yang J, Nobumoto A,
Tsuda M and Yokoyama A: Downregulation of miR-217 correlates with
resistance of Ph+ leukemia cells to ABL tyrosine kinase
inhibitors. Cancer Sci. 105:297–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang WZ, Pu QH, Lin XH, Liu MY, Wu LR, Wu
QQ, Chen YH, Liao FF, Zhu JY and Jin XB: Silencing of miR-21
sensitizes CML CD34+ stem/progenitor cells to
imatinib-induced apoptosis by blocking PI3K/AKT pathway. Leuk Res.
39:1117–1124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun C, Li N, Yang Z, Zhou B, He Y, Weng D,
Fang Y, Wu P, Chen P, Yang X, et al: miR-9 regulation of BRCA1 and
ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl
Cancer Inst. 105:1750–1758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Zhang W, Zuo Y, Ding M, Ke C, Yan
R, Zhan H, Liu J and Wang J: miR-9 promotes cell proliferation and
inhibits apoptosis by targeting LASS2 in bladder cancer. Tumour
Biol. 36:9631–9640. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kovalchuk O, Filkowski J, Meservy J,
Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement
of microRNA-451 in resistance of the MCF-7 breast cancer cells to
chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu H, Wu H, Liu X, Evans BR, Medina DJ,
Liu CG and Yang JM: Role of MicroRNA miR-27a and miR-451 in the
regulation of MDR1/P-glycoprotein expression in human cancer
cells. Biochem Pharmacol. 76:582–588. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng DD, Zhang H, Zhang P, Zheng YS, Zhang
XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, et al: Down-regulated
miR-331-5p and miR-27a are associated with chemotherapy resistance
and relapse in leukaemia. J Cell Mol Med. 15:2164–2175. 2011.
View Article : Google Scholar : PubMed/NCBI
|
